Aprea Therapeutics (NASDAQ:APRE – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Aprea Therapeutics to post earnings of ($0.69) per share and revenue of $0.15 million for the quarter.
Aprea Therapeutics Trading Down 1.2 %
APRE stock opened at $2.39 on Monday. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $6.80. The business’s 50-day moving average is $3.18 and its 200 day moving average is $3.27. The stock has a market cap of $12.99 million, a price-to-earnings ratio of -0.85 and a beta of 0.82.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Recommended Stories
- Five stocks we like better than Aprea Therapeutics
- 5 discounted opportunities for dividend growth investors
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- How to Profit From Value Investing
- 3 ETFs to Ride the VIX Surge During Market Volatility
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
